Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Vogel, A; Cervantes, A; Chau, I; Daniele, B; Llovet, J; Meyer, T; Nault, J-C; Neumann, U; Ricke, J; Sangro, B; Schirmacher, P; Verslype, C; Zech, CJ; Arnold, D; Martinelli, E

doi:10.1093/annonc/mdy308

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author:

Vogel, A

Cervantes, A ; Chau, I ; Daniele, B ; Llovet, J ; Meyer, T ; Nault, J-C ; Neumann, U ; Ricke, J ; Sangro, B ; Schirmacher, P ; Verslype, C ; Zech, CJ ; Arnold, D ; Martinelli, E

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, RANDOMIZED CONTROLLED-TRIAL, INTERNAL RADIATION-THERAPY, DOXORUBICIN-ELUTING BEADS, TRANSARTERIAL CHEMOEMBOLIZATION, RADIOFREQUENCY ABLATION, LIVER-TRANSPLANTATION, DOUBLE-BLIND, HEPATOBILIARY PHASE, PREDICT SURVIVAL, OPEN-LABEL, Ablation Techniques, Aftercare, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Brachytherapy, Carcinoma, Hepatocellular, Disease Progression, Early Detection of Cancer, Europe, Fatty Liver, Hepatectomy, Humans, Incidence, Liver, Liver Cirrhosis, Liver Neoplasms, Liver Transplantation, Mass Screening, Medical Oncology, Neoplasm Staging, Precision Medicine, Radiosurgery, Risk Assessment, Societies, Medical, Survivorship, Treatment Outcome, ESMO Guidelines Committee, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis